You are using an older browser version. Please use a supported version for the best MSN experience.

CELLECTAR BIOSCIENCES, INC.

NASDAQ: CLRB
1.41
+0.07
+5.22%

Sector

Healthcare

Industry

Pharmaceuticals

Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer-targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. Its PDC therapeutic, CLR 131 is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. The Company’s product pipeline also includes one preclinical PDC chemotherapeutic program (CLR 1900). The CLR 1900 Series is targeted for solid tumors with a payload that inhibits mitosis a validated pathway for treating cancers.

Key People

Stephen Anthony Hill

Chairman of the Board

James V. Caruso

President, Chief Executive Officer, Director

Cameron Szakacs

Vice President - Clinical Development

Jarrod Longcor

Chief Business Officer

Frederick W. Driscoll

Director

  • Cellectar Biosciences Inc

  • 100 Campus Dr

  • FLORHAM PARK, NJ 07932-1020

  • US.Map

  • Phone: +1 608 4418120

  • Fax: +1 608 4418121

  • cellectar.com

Incorporated

1996

Employees

8

Insider Trades
  • Recent
  • All
  • Date

  • Name

  • Transaction

  • Shares

  • Price(s)

  • Value

    • 6/5/2020

    • LONGCOR JARROD

    • Bought

    • 65,218

    • 1.15

    • 74,674.61

    • 6/5/2020

    • ELEFANT DOV

    • Bought

    • 4,348

    • 1.15

    • 4,978.46

    • 6/5/2020

    • CARUSO JAMES V

    • Bought

    • 21,740

    • 1.15

    • 24,892.30

    • 6/4/2020

    • HILL STEPHEN A

    • Bought

    • 18,000

    • 1.08

    • 19,438.20

    • 2/3/2020

    • CARUSO JAMES V

    • Grant

    • 100,000

    • 2.71

    • 271,000.00

    • 2/3/2020

    • LONGCOR JARROD

    • Grant

    • 40,000

    • 2.71

    • 108,400.00

    • 2/3/2020

    • ELEFANT DOV

    • Grant

    • 10,000

    • 2.71

    • 27,100.00

    • 2/3/2020

    • CARUSO JAMES V

    • Grant

    • 100,000

    • 2.71

    • 271,000.00

    • Date

    • Name

    • Transaction

    • Shares

    • Price(s)

    • Value

      • 6/5/2020

      • LONGCOR JARROD

      • Bought

      • 65,218

      • 1.15

      • 74,674.61

      • 6/5/2020

      • ELEFANT DOV

      • Bought

      • 4,348

      • 1.15

      • 4,978.46

      • 6/5/2020

      • CARUSO JAMES V

      • Bought

      • 21,740

      • 1.15

      • 24,892.30

      • 6/4/2020

      • HILL STEPHEN A

      • Bought

      • 18,000

      • 1.08

      • 19,438.20

      • 2/3/2020

      • CARUSO JAMES V

      • Grant

      • 100,000

      • 2.71

      • 271,000.00

      • 2/3/2020

      • LONGCOR JARROD

      • Grant

      • 40,000

      • 2.71

      • 108,400.00

      • 2/3/2020

      • ELEFANT DOV

      • Grant

      • 10,000

      • 2.71

      • 27,100.00

      • 2/3/2020

      • CARUSO JAMES V

      • Grant

      • 100,000

      • 2.71

      • 271,000.00

      AdChoices
      AdChoices
      AdChoices
      image beaconimage beaconimage beacon